A Phase 3 interventional study of Synercid in Gram-Positive Bacterial Infections, sponsored by Pfizer. Terminated at 6 sites in United States. Open to participants aged 27 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2012-05-25.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.
658 studies on the registry are indexed under Bacterial Infections; 100 are open to participants now.
Browse Bacterial Infections studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Population pharmacokinetics
Safety
Efficacy
This study is terminated, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer